<!DOCTYPE html>
<!-- Generated by pkgdown: do not edit by hand --><html lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><meta charset="utf-8"><meta http-equiv="X-UA-Compatible" content="IE=edge"><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><meta name="description" content="The optimal_multitrial_normal function enables planning of phase II/III
drug development programs with several phase III trials for
the same normally distributed endpoint. Its main output values are optimal
sample size allocation and go/no-go decision rules. For normally distributed
endpoints, the treatment effect is measured by the standardized difference in
means (Delta). The assumed true treatment effects can be assumed fixed or
modelled by a prior distribution."><title>Optimal phase II/III drug development planning where several phase III trials are performed — optimal_multitrial_normal • drugdevelopR</title><script src="../deps/jquery-3.6.0/jquery-3.6.0.min.js"></script><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><link href="../deps/bootstrap-5.2.2/bootstrap.min.css" rel="stylesheet"><script src="../deps/bootstrap-5.2.2/bootstrap.bundle.min.js"></script><!-- Font Awesome icons --><link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.1/css/all.min.css" integrity="sha256-mmgLkCYLUQbXn0B1SRqzHar6dCnv9oZFPEC1g1cwlkk=" crossorigin="anonymous"><link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.1/css/v4-shims.min.css" integrity="sha256-wZjR52fzng1pJHwx4aV2AO3yyTOXrcDW7jBpJtTwVxw=" crossorigin="anonymous"><!-- bootstrap-toc --><script src="https://cdn.jsdelivr.net/gh/afeld/bootstrap-toc@v1.0.1/dist/bootstrap-toc.min.js" integrity="sha256-4veVQbu7//Lk5TSmc7YV48MxtMy98e26cf5MrgZYnwo=" crossorigin="anonymous"></script><!-- headroom.js --><script src="https://cdnjs.cloudflare.com/ajax/libs/headroom/0.11.0/headroom.min.js" integrity="sha256-AsUX4SJE1+yuDu5+mAVzJbuYNPHj/WroHuZ8Ir/CkE0=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/headroom/0.11.0/jQuery.headroom.min.js" integrity="sha256-ZX/yNShbjqsohH1k95liqY9Gd8uOiE1S4vZc+9KQ1K4=" crossorigin="anonymous"></script><!-- clipboard.js --><script src="https://cdnjs.cloudflare.com/ajax/libs/clipboard.js/2.0.6/clipboard.min.js" integrity="sha256-inc5kl9MA1hkeYUt+EC3BhlIgyp/2jDIyBLS6k3UxPI=" crossorigin="anonymous"></script><!-- search --><script src="https://cdnjs.cloudflare.com/ajax/libs/fuse.js/6.4.6/fuse.js" integrity="sha512-zv6Ywkjyktsohkbp9bb45V6tEMoWhzFzXis+LrMehmJZZSys19Yxf1dopHx7WzIKxr5tK2dVcYmaCk2uqdjF4A==" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/autocomplete.js/0.38.0/autocomplete.jquery.min.js" integrity="sha512-GU9ayf+66Xx2TmpxqJpliWbT5PiGYxpaG8rfnBEk1LL8l1KGkRShhngwdXK1UgqhAzWpZHSiYPc09/NwDQIGyg==" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/mark.min.js" integrity="sha512-5CYOlHXGh6QpOFA/TeTylKLWfB3ftPsde7AnmhuitiTX4K5SqCLBeKro6sPS8ilsz1Q4NRx3v8Ko2IBiszzdww==" crossorigin="anonymous"></script><!-- pkgdown --><script src="../pkgdown.js"></script><meta property="og:title" content="Optimal phase II/III drug development planning where several phase III trials are performed — optimal_multitrial_normal"><meta property="og:description" content="The optimal_multitrial_normal function enables planning of phase II/III
drug development programs with several phase III trials for
the same normally distributed endpoint. Its main output values are optimal
sample size allocation and go/no-go decision rules. For normally distributed
endpoints, the treatment effect is measured by the standardized difference in
means (Delta). The assumed true treatment effects can be assumed fixed or
modelled by a prior distribution."><!-- mathjax --><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/MathJax.js" integrity="sha256-nvJJv9wWKEm88qvoQl9ekL2J+k/RWIsaSScxxlsrv8k=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/config/TeX-AMS-MML_HTMLorMML.js" integrity="sha256-84DKXVJXs0/F8OTMzX4UR909+jtl4G7SPypPavF+GfA=" crossorigin="anonymous"></script><!--[if lt IE 9]>
<script src="https://oss.maxcdn.com/html5shiv/3.7.3/html5shiv.min.js"></script>
<script src="https://oss.maxcdn.com/respond/1.4.2/respond.min.js"></script>
<![endif]--></head><body>
    <a href="#main" class="visually-hidden-focusable">Skip to contents</a>
    

    <nav class="navbar fixed-top navbar-light navbar-expand-lg bg-light"><div class="container">
    
    <a class="navbar-brand me-2" href="../index.html">drugdevelopR</a>

    <small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="">0.1.0</small>

    
    <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbar" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
      <span class="navbar-toggler-icon"></span>
    </button>

    <div id="navbar" class="collapse navbar-collapse ms-3">
      <ul class="navbar-nav me-auto"><li class="active nav-item">
  <a class="nav-link" href="../reference/index.html">Reference</a>
</li>
<li class="nav-item dropdown">
  <a href="#" class="nav-link dropdown-toggle" data-bs-toggle="dropdown" role="button" aria-expanded="false" aria-haspopup="true" id="dropdown-articles">Articles</a>
  <div class="dropdown-menu" aria-labelledby="dropdown-articles">
    <a class="dropdown-item" href="../articles/Bias_adjustment.html">Methods for Discounting of Phase II Results - Bias Adjustment</a>
    <a class="dropdown-item" href="../articles/Binary_distributed_outcomes.html">Binary Distributed Outcome Variables</a>
    <a class="dropdown-item" href="../articles/Fixed_and_prior_distributions.html">Fixed effects and prior distributions</a>
    <a class="dropdown-item" href="../articles/Interpreting_Output.html">Interpreting the Rest of the Output</a>
    <a class="dropdown-item" href="../articles/More_Parameters.html">More Parameters to Adapt to Specific Settings and Individual Needs</a>
    <a class="dropdown-item" href="../articles/Multiarm_Trials.html">Multiarm - Methods for Multi-Arm Programs</a>
    <a class="dropdown-item" href="../articles/Multiple_Endpoints.html">Programs for Trials with Multiple Endpoints</a>
    <a class="dropdown-item" href="../articles/Multitrial.html">Multitrial Programs - Methods for Programs with Several Phase III Trials</a>
    <a class="dropdown-item" href="../articles/Time-to-event_outcomes.html">Time-to-event Outcome Variables</a>
    <a class="dropdown-item" href="../articles/introduction-to-drugdevelopR.html">Introduction to planning phase II and phase III trials with drugdevelopR</a>
  </div>
</li>
<li class="nav-item">
  <a class="nav-link" href="../news/index.html">Changelog</a>
</li>
      </ul><form class="form-inline my-2 my-lg-0" role="search">
        <input type="search" class="form-control me-sm-2" aria-label="Toggle navigation" name="search-input" data-search-index="../search.json" id="search-input" placeholder="Search for" autocomplete="off"></form>

      <ul class="navbar-nav"><li class="nav-item">
  <a class="external-link nav-link" href="https://github.com/Sterniii3/drugdevelopR/" aria-label="github">
    <span class="fab fa fab fa-github fa-lg"></span>
     
  </a>
</li>
      </ul></div>

    
  </div>
</nav><div class="container template-reference-topic">
<div class="row">
  <main id="main" class="col-md-9"><div class="page-header">
      <img src="" class="logo" alt=""><h1>Optimal phase II/III drug development planning where several phase III trials are performed</h1>
      <small class="dont-index">Source: <a href="https://github.com/Sterniii3/drugdevelopR/blob/HEAD/R/optimal_multitrial_normal.R" class="external-link"><code>R/optimal_multitrial_normal.R</code></a></small>
      <div class="d-none name"><code>optimal_multitrial_normal.Rd</code></div>
    </div>

    <div class="ref-description section level2">
    <p>The <code>optimal_multitrial_normal</code> function enables planning of phase II/III
drug development programs with several phase III trials for
the same normally distributed endpoint. Its main output values are optimal
sample size allocation and go/no-go decision rules. For normally distributed
endpoints, the treatment effect is measured by the standardized difference in
means (Delta). The assumed true treatment effects can be assumed fixed or
modelled by a prior distribution.</p>
    </div>

    <div class="section level2">
    <h2 id="ref-usage">Usage<a class="anchor" aria-label="anchor" href="#ref-usage"></a></h2>
    <div class="sourceCode"><pre class="sourceCode r"><code><span><span class="fu">optimal_multitrial_normal</span><span class="op">(</span></span>
<span>  <span class="va">w</span>,</span>
<span>  <span class="va">Delta1</span>,</span>
<span>  <span class="va">Delta2</span>,</span>
<span>  <span class="va">in1</span>,</span>
<span>  <span class="va">in2</span>,</span>
<span>  <span class="va">a</span>,</span>
<span>  <span class="va">b</span>,</span>
<span>  <span class="va">n2min</span>,</span>
<span>  <span class="va">n2max</span>,</span>
<span>  <span class="va">stepn2</span>,</span>
<span>  <span class="va">kappamin</span>,</span>
<span>  <span class="va">kappamax</span>,</span>
<span>  <span class="va">stepkappa</span>,</span>
<span>  <span class="va">alpha</span>,</span>
<span>  <span class="va">beta</span>,</span>
<span>  <span class="va">c2</span>,</span>
<span>  <span class="va">c3</span>,</span>
<span>  <span class="va">c02</span>,</span>
<span>  <span class="va">c03</span>,</span>
<span>  K <span class="op">=</span> <span class="cn">Inf</span>,</span>
<span>  N <span class="op">=</span> <span class="cn">Inf</span>,</span>
<span>  S <span class="op">=</span> <span class="op">-</span><span class="cn">Inf</span>,</span>
<span>  <span class="va">b1</span>,</span>
<span>  <span class="va">b2</span>,</span>
<span>  <span class="va">b3</span>,</span>
<span>  <span class="va">case</span>,</span>
<span>  strategy <span class="op">=</span> <span class="cn">TRUE</span>,</span>
<span>  fixed <span class="op">=</span> <span class="cn">FALSE</span>,</span>
<span>  num_cl <span class="op">=</span> <span class="fl">1</span></span>
<span><span class="op">)</span></span></code></pre></div>
    </div>

    <div class="section level2">
    <h2 id="arguments">Arguments<a class="anchor" aria-label="anchor" href="#arguments"></a></h2>
    <dl><dt>w</dt>
<dd><p>weight for
<a href="https://web.imbi.uni-heidelberg.de/prior/" class="external-link">mixture prior distribution</a></p></dd>


<dt>Delta1</dt>
<dd><p>assumed true prior treatment effect measured as the
standardized difference in means, see
<a href="https://web.imbi.uni-heidelberg.de/prior/" class="external-link">here</a> for details</p></dd>


<dt>Delta2</dt>
<dd><p>assumed true prior treatment effect measured as the
standardized difference in means, see
<a href="https://web.imbi.uni-heidelberg.de/prior/" class="external-link">here</a> for details</p></dd>


<dt>in1</dt>
<dd><p>amount of information for <code>Delta1</code> in terms of sample size, see
<a href="https://web.imbi.uni-heidelberg.de/prior/" class="external-link">here</a>
for details</p></dd>


<dt>in2</dt>
<dd><p>amount of information for <code>Delta2</code> in terms of sample size, see
<a href="https://web.imbi.uni-heidelberg.de/prior/" class="external-link">here</a>
for details</p></dd>


<dt>a</dt>
<dd><p>lower boundary for the truncation of the <a href="https://web.imbi.uni-heidelberg.de/prior/" class="external-link">prior distribution</a></p></dd>


<dt>b</dt>
<dd><p>upper boundary for the truncation of the <a href="https://web.imbi.uni-heidelberg.de/prior/" class="external-link">prior distribution</a></p></dd>


<dt>n2min</dt>
<dd><p>minimal total sample size for phase II; must be an even number</p></dd>


<dt>n2max</dt>
<dd><p>maximal total sample size for phase II, must be an even number</p></dd>


<dt>stepn2</dt>
<dd><p>step size for the optimization over n2; must be an even number</p></dd>


<dt>kappamin</dt>
<dd><p>minimal threshold value kappa for the go/no-go decision rule</p></dd>


<dt>kappamax</dt>
<dd><p>maximal threshold value  kappa for the go/no-go decision rule</p></dd>


<dt>stepkappa</dt>
<dd><p>step size for the optimization over the threshold value kappa</p></dd>


<dt>alpha</dt>
<dd><p>significance level</p></dd>


<dt>beta</dt>
<dd><p>type II error rate; i.e. <code>1 - beta</code> is the power for calculation of the sample size for phase III</p></dd>


<dt>c2</dt>
<dd><p>variable per-patient cost for phase II in 10^5 $</p></dd>


<dt>c3</dt>
<dd><p>variable per-patient cost for phase III in 10^5 $</p></dd>


<dt>c02</dt>
<dd><p>fixed cost for phase II in 10^5 $</p></dd>


<dt>c03</dt>
<dd><p>fixed cost for phase III in 10^5 $</p></dd>


<dt>K</dt>
<dd><p>constraint on the costs of the program, default: Inf, e.g. no constraint</p></dd>


<dt>N</dt>
<dd><p>constraint on the total expected sample size of the program, default: Inf, e.g. no constraint</p></dd>


<dt>S</dt>
<dd><p>constraint on the expected probability of a successful program, default: -Inf, e.g. no constraint</p></dd>


<dt>b1</dt>
<dd><p>expected gain for effect size category "small" in 10^5 $</p></dd>


<dt>b2</dt>
<dd><p>expected gain for effect size category "medium" in 10^5 $</p></dd>


<dt>b3</dt>
<dd><p>expected gain for effect size category "large" in 10^5 $</p></dd>


<dt>case</dt>
<dd><p>choose case: "at least 1, 2 or 3 significant trials needed for approval"</p></dd>


<dt>strategy</dt>
<dd><p>choose strategy: "conduct 1, 2, 3 or 4 trials in order to achieve the case's goal"; TRUE calculates all strategies of the selected <code>case</code></p></dd>


<dt>fixed</dt>
<dd><p>choose if true treatment effects are fixed or following a prior distribution, if TRUE <code>Delta1</code> is used as fixed effect</p></dd>


<dt>num_cl</dt>
<dd><p>number of clusters used for parallel computing, default: 1</p></dd>

</dl></div>
    <div class="section level2">
    <h2 id="value">Value<a class="anchor" aria-label="anchor" href="#value"></a></h2>
    

<p>The output of the function is a <code>data.frame</code> object containing the optimization results:</p><dl><dt>Strategy</dt>
<dd><p>Strategy: "number of trials to be conducted in order to achieve the goal of the case"</p></dd>
<dt>u</dt>
<dd><p>maximal expected utility under the optimization constraints, i.e. the expected utility of the optimal sample size and threshold value</p></dd>
<dt>Kappa</dt>
<dd><p>optimal threshold value for the decision rule to go to phase III</p></dd>
<dt>n2</dt>
<dd><p>total sample size for phase II; rounded to the next even natural number</p></dd>

<dt>n3</dt>
<dd><p>total sample size for phase III; rounded to the next even natural number</p></dd>

<dt>n</dt>
<dd><p>total sample size in the program; n = n2 + n3</p></dd>

<dt>K</dt>
<dd><p>maximal costs of the program</p></dd>

<dt>pgo</dt>
<dd><p>probability to go to phase III</p></dd>

<dt>sProg</dt>
<dd><p>probability of a successful program</p></dd>

<dt>sProg1</dt>
<dd><p>probability of a successful program with "small" treatment effect in phase III (lower boundary in HR scale is set to 0, as proposed by Cohen (1988))</p></dd>

<dt>sProg2</dt>
<dd><p>probability of a successful program with "medium" treatment effect in phase III (lower boundary in HR scale is set to 0.5, as proposed Cohen (1988))</p></dd>

<dt>sProg3</dt>
<dd><p>probability of a successful program with "large" treatment effect in phase III (lower boundary in HR scale is set to 0.8, as proposed Cohen (1988))</p></dd>

<dt>K2</dt>
<dd><p>expected costs for phase II</p></dd>

<dt>K3</dt>
<dd><p>expected costs for phase III</p></dd>

</dl><p>and further input parameters. Taking <code>cat(comment())</code> of the
data frame lists the used optimization sequences, start and
finish date of the optimization procedure.</p>
    </div>
    <div class="section level2">
    <h2 id="details">Details<a class="anchor" aria-label="anchor" href="#details"></a></h2>
    <p>The R Shiny application <a href="https://web.imbi.uni-heidelberg.de/prior/" class="external-link">prior</a>
visualizes the prior distributions used in this package. Fast computing is
enabled by parallel programming.</p>
    </div>
    <div class="section level2">
    <h2 id="effect-sizes">Effect sizes<a class="anchor" aria-label="anchor" href="#effect-sizes"></a></h2>
    

<p>In other settings, the definition of "small", "medium" and "large" effect
sizes can be user-specified using the input parameters <code>steps1</code>, <code>stepm1</code> and
<code>stepl1</code>. Due to the complexity of the multitrial setting, this feature is
not included for this setting. Instead, the effect sizes were set to
to predefined values as explained under sProg1, sProg2 and sProg3 in the
<em>Value</em> section.</p>
    </div>
    <div class="section level2">
    <h2 id="references">References<a class="anchor" aria-label="anchor" href="#references"></a></h2>
    <p>Cohen, J. (1988). Statistical power analysis for the behavioral sciences.</p>
    </div>
    <div class="section level2">
    <h2 id="last-edited-by">Last Edited By<a class="anchor" aria-label="anchor" href="#last-edited-by"></a></h2>
    <p>Johannes Cepicka</p>
    </div>
    <div class="section level2">
    <h2 id="last-edit-date">Last Edit Date<a class="anchor" aria-label="anchor" href="#last-edit-date"></a></h2>
    <p>2022-04-23</p>
    </div>

    <div class="section level2">
    <h2 id="ref-examples">Examples<a class="anchor" aria-label="anchor" href="#ref-examples"></a></h2>
    <div class="sourceCode"><pre class="sourceCode r"><code><span class="r-in"><span><span class="va">res</span> <span class="op">&lt;-</span> <span class="fu">optimal_multitrial_normal</span><span class="op">(</span>w <span class="op">=</span> <span class="fl">0.3</span>,                <span class="co"># define parameters for prior</span></span></span>
<span class="r-in"><span>  Delta1 <span class="op">=</span> <span class="fl">0.375</span>, Delta2 <span class="op">=</span> <span class="fl">0.625</span>, in1 <span class="op">=</span> <span class="fl">300</span>, in2 <span class="op">=</span> <span class="fl">600</span>,  <span class="co"># (https://web.imbi.uni-heidelberg.de/prior/)</span></span></span>
<span class="r-in"><span>  a <span class="op">=</span> <span class="fl">0.25</span>, b <span class="op">=</span> <span class="fl">0.75</span>,</span></span>
<span class="r-in"><span>  n2min <span class="op">=</span> <span class="fl">20</span>, n2max <span class="op">=</span> <span class="fl">100</span>, stepn2 <span class="op">=</span> <span class="fl">4</span>,                   <span class="co"># define optimization set for n2</span></span></span>
<span class="r-in"><span>  kappamin <span class="op">=</span> <span class="fl">0.02</span>, kappamax <span class="op">=</span> <span class="fl">0.2</span>, stepkappa <span class="op">=</span> <span class="fl">0.02</span>,     <span class="co"># define optimization set for kappa</span></span></span>
<span class="r-in"><span>  alpha <span class="op">=</span> <span class="fl">0.05</span>, beta <span class="op">=</span> <span class="fl">0.1</span>,                              <span class="co"># drug development planning parameters</span></span></span>
<span class="r-in"><span>  c2 <span class="op">=</span> <span class="fl">0.675</span>, c3 <span class="op">=</span> <span class="fl">0.72</span>, c02 <span class="op">=</span> <span class="fl">15</span>, c03 <span class="op">=</span> <span class="fl">20</span>,             <span class="co"># define fixed and variable costs for phase II and III</span></span></span>
<span class="r-in"><span>  K <span class="op">=</span> <span class="cn">Inf</span>, N <span class="op">=</span> <span class="cn">Inf</span>, S <span class="op">=</span> <span class="op">-</span><span class="cn">Inf</span>,                            <span class="co"># set constraints</span></span></span>
<span class="r-in"><span>  b1 <span class="op">=</span> <span class="fl">3000</span>, b2 <span class="op">=</span> <span class="fl">8000</span>, b3 <span class="op">=</span> <span class="fl">10000</span>,                      <span class="co"># define expected benefit for a "small", "medium" and "large" treatment effect                                             # assume different/same population structures in phase II and III</span></span></span>
<span class="r-in"><span>  case <span class="op">=</span> <span class="fl">1</span>, strategy <span class="op">=</span> <span class="cn">TRUE</span>,                             <span class="co"># chose Case and Strategy</span></span></span>
<span class="r-in"><span>  fixed <span class="op">=</span> <span class="cn">TRUE</span>,                                          <span class="co"># choose if true treatment effects are fixed or random</span></span></span>
<span class="r-in"><span>  num_cl <span class="op">=</span> <span class="fl">1</span><span class="op">)</span>                                            <span class="co"># set number of cores used for parallelized computing</span></span></span>
<span class="r-out co"><span class="r-pr">#&gt;</span> </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> Case  1 : Optimization progess for Strategy  1</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>   |                                                                              |                                                                      |   0%  |                                                                              |=======                                                               |  10%  |                                                                              |==============                                                        |  20%  |                                                                              |=====================                                                 |  30%  |                                                                              |============================                                          |  40%  |                                                                              |===================================                                   |  50%  |                                                                              |==========================================                            |  60%  |                                                                              |=================================================                     |  70%  |                                                                              |========================================================              |  80%  |                                                                              |===============================================================       |  90%  |                                                                              |======================================================================| 100%</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> Case  1 : Optimization progess for Strategy  2</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>   |                                                                              |                                                                      |   0%  |                                                                              |=======                                                               |  10%  |                                                                              |==============                                                        |  20%  |                                                                              |=====================                                                 |  30%  |                                                                              |============================                                          |  40%  |                                                                              |===================================                                   |  50%  |                                                                              |==========================================                            |  60%  |                                                                              |=================================================                     |  70%  |                                                                              |========================================================              |  80%  |                                                                              |===============================================================       |  90%  |                                                                              |======================================================================| 100%</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> Optimization result:</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>   Case Strategy       u Kappa  n2  n3   n  pgo sProg Delta   K   N    S K2  K3</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 1    1        1 1890.94  0.10 100 376 476 0.92  0.74 0.375 Inf Inf -Inf 82 289</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 2    1        2 1928.79  0.12 100 656 756 0.90  0.82 0.375 Inf Inf -Inf 82 508</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>   sProg1 sProg2 sProg3 steps1 stepm1 stepl1 alpha beta c02 c03    c2   c3   b1</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 1   0.74   0.01      0      0    0.5    0.8  0.05  0.1  15  20 0.675 0.72 3000</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 2   0.81   0.01      0      0    0.5    0.8  0.05  0.1  15  20 0.675 0.72 3000</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>     b2    b3</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 1 8000 10000</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 2 8000 10000</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> </span>
<span class="r-in"><span><span class="va">res</span></span></span>
<span class="r-out co"><span class="r-pr">#&gt;</span>   Case Strategy       u Kappa  n2  n3   n  pgo sProg Delta   K   N    S K2  K3</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 1    1        1 1890.94  0.10 100 376 476 0.92  0.74 0.375 Inf Inf -Inf 82 289</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 2    1        2 1928.79  0.12 100 656 756 0.90  0.82 0.375 Inf Inf -Inf 82 508</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>   sProg1 sProg2 sProg3 steps1 stepm1 stepl1 alpha beta c02 c03    c2   c3   b1</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 1   0.74   0.01      0      0    0.5    0.8  0.05  0.1  15  20 0.675 0.72 3000</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 2   0.81   0.01      0      0    0.5    0.8  0.05  0.1  15  20 0.675 0.72 3000</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>     b2    b3</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 1 8000 10000</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 2 8000 10000</span>
<span class="r-in"><span></span></span>
<span class="r-in"><span><span class="fu"><a href="https://rdrr.io/r/base/cat.html" class="external-link">cat</a></span><span class="op">(</span><span class="fu"><a href="https://rdrr.io/r/base/comment.html" class="external-link">comment</a></span><span class="op">(</span><span class="va">res</span><span class="op">)</span><span class="op">)</span>                                        <span class="co"># displays the optimization sequence, start/ finish date of procedure.</span></span></span>
<span class="r-out co"><span class="r-pr">#&gt;</span> </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> optimization sequence kappa: 0.02 0.04 0.06 0.08 0.1 0.12 0.14 0.16 0.18 0.2 </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> optimization sequence n2: 20 24 28 32 36 40 44 48 52 56 60 64 68 72 76 80 84 88 92 96 100 </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> set on date: 2023-03-27 11:16:44 </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> finish date: 2023-03-27 11:18:03</span>
<span class="r-in"><span></span></span>
<span class="r-in"><span></span></span>
</code></pre></div>
    </div>
  </main><aside class="col-md-3"><nav id="toc"><h2>On this page</h2>
    </nav></aside></div>


    <footer><div class="pkgdown-footer-left">
  <p></p><p>Developed by Stella Preussler.</p>
</div>

<div class="pkgdown-footer-right">
  <p></p><p>Site built with <a href="https://pkgdown.r-lib.org/" class="external-link">pkgdown</a> 2.0.7.</p>
</div>

    </footer></div>

  

  

  </body></html>

